ITM2B Gene Familial Danish Dementia (FDD) Genetic Test in UAE | 2,800 AED | DHA Licensed

Executive Summary & Core Metrics

Executive Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Next-Generation Sequencing covering the full ITM2B gene with copy number variant detection.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across all seven emirates.
Clinical Guidance: Post-test telephonic counselling by DHA-licensed Consultant Medical Geneticist with pedigree analysis and hereditary risk stratification.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The ITM2B Gene Familial Danish Dementia (FDD) Genetic Test detects pathogenic and likely pathogenic variants in the ITM2B gene responsible for autosomal dominant cerebral amyloid angiopathy with early-onset dementia. This comprehensive analysis utilises high-coverage next-generation sequencing on the Illumina platform with clinical-grade bioinformatics pipeline validated under ISO 15189 standards. The test delivers a definitive molecular diagnosis within 3 to 4 weeks from sample receipt, enabling accurate genetic counselling and family cascade screening.

Feature	Our Test (ITM2B NGS)	Closest Alternative
Precision & Sensitivity	99.9% sensitivity; full gene sequencing with copy number variant (CNV) detection and splice-site analysis	Targeted single-variant Sanger sequencing; approximately 95% sensitivity for known founder mutations only
Methodology	Next-Generation Sequencing (NGS) on Illumina platform, ISO 15189 validated with >100x mean coverage	Sanger sequencing limited to one exon or a single known pathogenic variant
Turnaround Time	3–4 weeks (express processing available reducing to 15 business days)	4–6 weeks

Physician Insight & Safety Protocols

“A pathogenic variant in the ITM2B gene confirms a hereditary predisposition to Familial Danish Dementia, a rare autosomal dominant cerebral amyloid angiopathy. Correlation with neuroimaging, cognitive assessment, and detailed three-generation pedigree analysis is essential before any clinical management decisions are made. This molecular result provides clarity for the patient and at-risk family members but must be contextualised within a comprehensive specialist evaluation. Genetic counselling before and after testing is mandatory to address psychosocial implications and cascade screening options.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Medication & Safety Advisory

Do not discontinue any prescribed medications or alter your treatment regimen without consulting your treating physician. Genetic testing provides diagnostic information and does not replace ongoing clinical management or emergency care. Results should be reviewed with a qualified genetics specialist before any lifestyle or therapeutic changes are implemented.

Exclusion Criteria & Urgent Red Flags

This genetic test is not indicated for minors under the age of medical consent without explicit parental authorisation and appropriate pre-test counselling.
Individuals unable to provide informed consent or who have not completed a mandatory pre-test genetic counselling session inclusive of a three-generation pedigree chart are ineligible for testing.
Emergency Red Flags: If the patient experiences sudden onset of severe confusion, unilateral paralysis, seizure, or loss of consciousness, proceed immediately to the nearest emergency department — genetic testing is not indicated for acute neurological deterioration and will not alter emergency management.

Patient FAQ & Clinical Guidance

1. What is the accuracy of the ITM2B genetic test for Familial Danish Dementia?

The test achieves 99.9% diagnostic sensitivity for known pathogenic variants in the ITM2B gene using high-coverage NGS with CNV detection. This ensures near-definitive hereditary assessment for symptomatic individuals and at-risk family members. Results are reported with ACMG/AMP classification guidelines.

2. How long does it take to receive results for the FDD genetic test?

Laboratory turnaround time is 3 to 4 weeks from sample receipt. Express processing is available upon request and may reduce the wait time to 15 business days. Results are delivered electronically via a secure patient portal and followed by a telephonic consultation with our Consultant Medical Geneticist.

3. Does insurance cover the ITM2B genetic test in the UAE?

Many UAE health insurance providers partially cover medically necessary genetic tests when supported by a neurologist's or geneticist's referral. Direct billing verification and pre-authorisation support are available via WhatsApp at +971 54 548 8731. Coverage varies by plan; we recommend confirming with your insurer prior to sample collection.

4. Is home sample collection available for this genetic test?

Yes. VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection are available daily from 8 AM to 11 PM across Dubai, Abu Dhabi, Sharjah, and all Northern Emirates. A certified phlebotomist will collect a peripheral whole blood sample (EDTA tube) at your residence or workplace. There is no additional charge for home collection within the greater Dubai area.

UAE Regulatory & Data Privacy Adherence

Data Protection & Legal Compliance

Your genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Genetic results are encrypted, access-controlled, and never shared with third parties without your explicit written consent. DNA Labs UAE is DHA-licensed and operates under ISO 15189 quality standards for molecular diagnostics.

Clinical & Logistical Metadata

Test Name	ITM2B Gene Familial Danish Dementia (FDD) Genetic Test – Full Gene Sequencing
Price (AED)	2,800 AED
Turnaround Time	3–4 weeks (express 15 business days available)
Sample Type / Matrix	Peripheral Whole Blood (EDTA) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM)
Methodology Used	Next-Generation Sequencing (NGS) – Illumina Platform, ISO 15189 Validated, >100x Mean Coverage with CNV Analysis
ICD-10-CM Code	G31.89, E85.4
LOINC Code	21636-6
DHA Facility License & Address	License No. 1143 \| DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE